Urology
Volume 74, Issue 4 , Pages 741-745 , October 2009

Efficacy and Safety of Oxybutynin Transdermal System in Spinal Cord Injury Patients With Neurogenic Detrusor Overactivity and Incontinence: An Open-label, Dose-titration Study

  • Michael J. Kennelly

      Affiliations

    • Carolinas Rehabilitation, Charlotte, North Carolina
    • Corresponding Author InformationReprint requests: Michael J. Kennelly, M.D., Carolinas Rehabilitation, Carolinas Healthcare System, 1100 Blythe Boulevard, Charlotte, NC 28203
    • ,
  • Gary E. Lemack

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Jenelle E. Foote

      Affiliations

    • Midtown Urology and Shepherd Center, Atlanta, Georgia
    • ,
  • Cynthia S. Trop

      Affiliations

    • James J. Peters VA Medical Center, Bronx, New York

Received 9 January 2009 ,Accepted 5 May 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This study was supported by Watson Laboratories, Inc, Morristown, New Jersey.

 Editorial assistance was provided by Scientific Connexions, Newtown, Pennsylvania.

 Relevant financial disclosures and conflicts of interest: Michael J. Kennelly. Watson Laboratories, Allergan, Pfizer–Study investigator and consultant and educator/speaker; GSK, Astellas, Novartis—Consultant and educator/speaker; Gary E. Lemack. Allergan–Research support/study site for clinical research; Astellas–Speaker; Novartis–Consultant and speaker; Pfizer–Consultant and speaker; Watson Laboratories–Study investigator (at the time of this study); Jenelle E. Foote. Pfizer–Detrol LA; Astellas/GSK–Vesicare advisory board, speakers bureau; Novartis–Enablex research support, speakers bureau; Allergan–Botox study research support; Pfizer–Fesoterodine research support, speakers bureau; Cynthia S. Trop. Watson Laboratories–Study investigator; Allergan–Botox study investigator.

PII: S0090-4295(09)00629-3

doi: 10.1016/j.urology.2009.05.008

Urology
Volume 74, Issue 4 , Pages 741-745 , October 2009

Article Tools

* Image Usage & Resolution